- Home
- PYN vs XAIR Comparison
PYN vs XAIR Comparison
Compare PYN & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- XAIR
- Stock Information
- Founded
- PYN 2002
- XAIR 2011
- Country
- PYN United States
- XAIR United States
- Employees
- PYN N/A
- XAIR N/A
- Industry
- PYN Investment Managers
- XAIR Medical/Dental Instruments
- Sector
- PYN Finance
- XAIR Health Care
- Exchange
- PYN Nasdaq
- XAIR Nasdaq
- Market Cap
- PYN 34.6M
- XAIR 34.7M
- IPO Year
- PYN N/A
- XAIR N/A
- Fundamental
- Price
- PYN $6.04
- XAIR $0.50
- Analyst Decision
- PYN
- XAIR Strong Buy
- Analyst Count
- PYN 0
- XAIR 4
- Target Price
- PYN N/A
- XAIR $3.67
- AVG Volume (30 Days)
- PYN 19.9K
- XAIR 636.5K
- Earning Date
- PYN 01-01-0001
- XAIR 11-11-2024
- Dividend Yield
- PYN 5.07%
- XAIR N/A
- EPS Growth
- PYN N/A
- XAIR N/A
- EPS
- PYN N/A
- XAIR N/A
- Revenue
- PYN N/A
- XAIR $2,342,000.00
- Revenue This Year
- PYN N/A
- XAIR $640.47
- Revenue Next Year
- PYN N/A
- XAIR $286.81
- P/E Ratio
- PYN N/A
- XAIR N/A
- Revenue Growth
- PYN N/A
- XAIR 685.91
- 52 Week Low
- PYN $4.84
- XAIR $0.30
- 52 Week High
- PYN $6.60
- XAIR $2.36
- Technical
- Relative Strength Index (RSI)
- PYN 45.93
- XAIR 56.04
- Support Level
- PYN $5.97
- XAIR $0.42
- Resistance Level
- PYN $6.11
- XAIR $0.56
- Average True Range (ATR)
- PYN 0.10
- XAIR 0.07
- MACD
- PYN 0.01
- XAIR 0.00
- Stochastic Oscillator
- PYN 33.43
- XAIR 47.32
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.